This trial is evaluating whether Encorafenib will improve 4 primary outcomes and 6 secondary outcomes in patients with Cancer of Skin. Measurement will happen over the course of Up to 28 days.
This trial requires 35 total participants across 1 different treatment group
This trial involves a single treatment. Encorafenib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The rate of metastatic spread to regional lymph nodes in stage III melanomas is very low (3%). The presence of ulceration correlated significantly with lymph node metastasis. No statistically significant difference was found between the infiltration-based T staging system and the lymph node involvement status. Whether the removal of the primary tumor before sentinel lymph node biopsy should be considered remains to be determined." - Anonymous Online Contributor
"Encouraging results have been obtained from clinical trials investigating the effectiveness of encorafenib as a targeted therapy for advanced melanoma. These data support further investigation of encorafenib as a potentially effective therapy for patients with metastatic melanoma." - Anonymous Online Contributor
"The majority of patients had detectable melanomas at the time they were diagnosed; however, many also had silent or asymptomatic lesions at this time. Most patients were diagnosed by examination. None had routine skin examinations or a history of sun exposure prior to diagnosis. Many patients already had at least one previous dermatological visit, even before their diagnosis of melanoma. All patients should have a full dermatologic exam when first presenting with symptoms suggestive of melanoma." - Anonymous Online Contributor
"Encouraging results have been obtained with intravenous administration of the MEK inhibitor, encorafenib. Recent findings should inspire further development of other MEK inhibitors as anti-cancer agents." - Anonymous Online Contributor
"Encouraging results from phase II trials have been reported and show that the combination therapy of encorafenib plus chemotherapy prolongs progression free survival compared with chemotherapy alone. Further studies to assess its usefulness in selected patients with advanced disease are warranted." - Anonymous Online Contributor
"Melanoma is a deadly disease that can affect anyone of any age, sex or race. It may appear as any type of mole, which is a dark spot on the skin, but which can change over time, becoming larger or smaller, darker or lighter, or even itchiness. A small percentage of moles become cancerous.\nMelanoma is a form of skin cancer that begins when normal cells grow out of control. Most often, this happens because the body doesn't produce enough tumor suppressor protein p53. Other factors include ultraviolet light exposure, sunburn, clustering of moles, genetics, family history of melanoma, and skin color." - Anonymous Online Contributor
"Encorafenib has shown promising activity in patients with advanced melanomas. Findings from a recent study support further study of encorafenib in patients with advanced melanomas, as well as in earlier stages of disease. The lack of dose-limiting toxicities in our study suggests that encorafenib can be used safely at standard doses in patients with advanced melanomas." - Anonymous Online Contributor
"The majority of patients who received encorafenib as monotherapy exhibited no improvement in disease progression-free survival or overall survival compared with those receiving placebo. Encorafenib was associated with increased rates of hepatotoxicity and pneumonitis." - Anonymous Online Contributor
"Encouraging results have been observed from the REGN-EB3 Phase II trial comparing encorafenib with dacarbazine plus temozolomide. Recent findings examined patients with advanced melanoma. Patients were randomized (1:1) to receive standard chemotherapy or encorafenib plus the same chemotherapy. Encorafenib was well tolerated, although it increased overall mortality and progression-free survival compared with standard chemotherapy. In particular, treatment with encorafenib resulted in increased rates of grade 3 or 4 adverse events and decreased rates of grade 3 or 4 responses." - Anonymous Online Contributor
"We can't predict whether someone will develop any type of cancer, including melanoma. However, there are certain factors that may help to determine how likely someone is to get melanoma. These include having a family member who had some type of cancer (e.g., melanoma) or having a history of skin cancer. Studying your family history for melanoma or similar illnesses can help to identify your risk for developing the disease." - Anonymous Online Contributor